Day: June 5, 2022

BRISBANE, Australia, June 06, 2022 (GLOBE NEWSWIRE) — Allkem Limited (ASX|TSX: “AKE”, the “Company”) provides an update on product pricing and operations. Lithium carbonate Continued strong market conditions positively impacted the price received for lithium carbonate from the Olaroz Lithium Facility. The June quarter FY22 average price received for lithium carbonate is expected to be approximately 14% above prior guidance at US$40,000/t FOB1 on sales of approximately 3,500 tonnes. Customers continue to value security of supply which is reflected in a fully committed order book for the remainder of the calendar year. Spodumene Similarly strong conditions continue in the spodumene market with realised spodumene concentrate pricing in the June quarter of approximately US$5,000/t SC6% CIF. Shipped spodumene concentrate for the quarter...

Australian insurer shifts from on-prem to cloud for its policy, billing and rating core systems Boston, June 05, 2022 (GLOBE NEWSWIRE) — Duck Creek Technologies (Nasdaq: DCT), a leading, global technology solutions provider to the property and casualty (P&C) insurance industry, announces its latest partnership with Hollard Insurance to upgrade the Australian insurer’s core policy, billing and rating systems from on-premises to cloud-based software as a service (SaaS) using Duck Creek OnDemand. Duck Creek’s technology suite will enable Hollard to work with its other technology ecosystem partners using low-code tools and established integrations to develop and rapidly bring to market innovative products that satisfy evolving policyholder needs.  Hollard recently embarked on a technology-enabled business transformation to modernize...

Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast cancer patients with Cyclin D amplification Management and key opinion leaders to present results and provide update on expanded development of zotatifin in investor call on June 5th at 7 p.m. ET / 6 p.m. CT SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today reported positive interim results of the company’s ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed treatment was generally well tolerated, resulted in suppression...

Preliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genentech and conducted at Memorial Sloan Kettering Cancer Center, New York, United States Autogene Cevumeran, a fully individualized mRNA cancer immunotherapy (iNeST) demonstrated that vaccine-induced immunity significantly correlates with delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma Initial results suggest sequential combination of anti-PD-L1 checkpoint inhibitor atezolizumab with individualized cancer therapy autogene cevumeran, and chemotherapy showed a favorable safety profile, while the product candidate was feasibly manufactured in a clinically relevant timeframe BioNTech and Genentech plan to jointly initiate a randomized study of autogene cevumeran in adjuvant pancreatic...

34% overall response rate in 79 evaluable patients with measurable disease 9.1 months median duration of response Tumor reduction in 70% of patients Zeno observed to be very well-tolerated Potential new standard of care for patients with NRG1+ cancer Investor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CTUTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody Zeno in patients with NRG1+ cancer presented virtually by Lead Author,...

Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2 to proceed with alternating 2-vector therapy in combination with pembrolizumab, which will help inform the randomized Phase 2 trial with pembrolizumab planned to start in the first half of 2023Additional Phase 2 cohort will evaluate alternating 2-vector only therapy in post-standard of care settingNEW YORK and VIENNA, Austria, June 05, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human...

Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well tolerated BOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced presentation of the first preclinical data for LB101, PD-L1xCD47 LockBody, in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which is taking place virtually and in person from June 3-7, 2022 in Chicago, IL. The poster presentation will be featured in the Developmental Therapeutics – Immunotherapy session today, June 5, 2022, at 8-11...

— Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China – the facility is now expected to be ready for GMP inspections in Q3-2022 — — Regulatory submissions to the China NMPA, EMA, and the WHO for SCB-2019 (CpG 1018/Alum) are anticipated to be completed in the second half of 2022 — — Universal Booster Development: Phase 3 clinical trial evaluating SCB-2019 (CpG 1018/Alum) as a heterologous booster for CoronaVac™ and Comirnaty® expected to initiate in June 2022 — — Credit agreement with China Merchants Bank has been approved for up to US$300 million to support commercial launch of SCB-2019 — SHANGHAI, China, June 05, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology...